Two buzzy, well-funded biotech startups are combining in a bid to create a powerhouse at the bleeding edge of genetic medicines.
Orna Therapeutics announced Thursday that it would acquire ReNAgade Therapeutics in an all-equity transaction. The combined company will focus on RNA therapies that can reprogram blood and immune cells directly inside the body. If such in vivo approaches work, they could replace expensive and cumbersome cell therapies, including CAR-T therapies used to treat cancer and the new gene editing therapy for sickle cell disease. Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
BECOME A PREMIUM SUBSCRIBER